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We previously demonstrated that black bean (BB) and soy ﬂour (SF)-based diets inhibit azoxymethane (AOM)-induced colon
cancer. The objective of this study was to identify genes altered by carcinogen treatment in normal-appearing colonic mucosa and
thoseattenuated by bean feeding. Ninety-ﬁve maleF344 rats were fed control(AIN) diets upon arrival.At 4and 5 weeks, rats were
injected with AOM (15mg/kg) or saline and one week later administered an AIN, BB-, or SF-based diet. Rats were sacriﬁced after
31 weeks, and microarrays were conducted on RNA isolated from the distal colonic mucosa. AOM treatment induced a number
of genes involved in immunity, including several MHC II-associated antigens and innate defense genes (RatNP-3, Lyz2, Pla2g2a).
BB- and SF-fed rats exhibited a higher expression of genes involved in energy metabolism and water and sodium absorption and
lower expression of innate (RatNP-3, Pla2g2a, Tlr4, Dmbt1) and cell cycle-associated (C d c 2 ,C c n b 1 ,T o p 2 a ) genes. Genes involved
intheextracellular matrix(Col1a1, Fn1)andinnateimmunity(RatNP-3, Pla2g2a) were induced by AOMinalldiets, but to alower
extent in bean-fed animals. This proﬁle suggests beans inhibit colon carcinogenesis by modulating cellular kinetics and reducing
inﬂammation,potentially by preserving mucosal barrier function.
1.Introduction
Colorectal cancer (CRC) is one of the most common neo-
plasms aﬄicting industrialized societies [1]. In 2008, there
were609,051deathsduetocolorectalcancerworldwide, with
50,640 cases in the United States alone [1]. Both genetic
and environmental exposures have been implicated in the
etiology of CRC, and it has been estimated that up to 75%
of cases may be preventable by adequate diets and regular
exercise [2–4]. Consumption of diets low in red meat and
alcohol and high in vegetables and cereal grains is generally
associated with a decreased risk of developing CRC [4–
6]. Additionally, populations consuming higher intakes of
legumes (peas, beans, lentils, peanuts) are reported to have
al o w e rr i s ko f[ 6–12]a n dm o r t a l i t yf r o mC R C[ 13].
It has long been known that dietary patterns modu-
late the incidence and mortality of colorectal cancer [2, 3],
however, identiﬁcation of speciﬁc mechanisms has been lim-
ited. The azoxymethane- (AOM-) induced colon cancer
model in rodents has been utilized extensively to examine
dietary inﬂuences on colon cancer. Tumors develop almost
exclusivelyinthecolon,primarily in thedistalregion, similar
to the distribution observed in humans from high-risk areas.
Additionally, many of the common genetic and pathogenic
changes contributing to human colon cancers are also
observed during AOM-induced colon carcinogenesis [14–
19]. Although Apc mutations are infrequently detected [20],
mutations in GSK-3β phosphorylation consensus sites on
β-catenin are present in up to 77% of AOM-induced colon
cancers as well as in early preneoplastic lesions [17, 21–23].
These sites are important for downregulation of β-catenin
by ubiquitination and result in stabilization and nuclear
localization of the protein [23]. Activating mutations on
codon 12 and 13 of the k-ras gene [14, 15], upregulation of2 Journal of Nutrition and Metabolism
cyclo-oxygenase 2 (COX-2), and inducible nitric oxide
synthase (iNOS), as well as alterations in transforming
growth factor β signaling, are also common features to both
human and AOM-induced colon cancers [24–29]. Using this
model, experiments conducted in our laboratory [30–33]
and by others [34–36] have demonstrated the potential of
bean-based diets to inhibit AOM-induced colon cancer. For
example, Hughes et al. [35] and Hangen and Bennink [32]
found that rats fed dry beans (pinto, navy, or black beans)
had a 50–57% lower incidence of colon cancer than rats
fed a casein-based diet. Similarly, in a series of experiments,
Bennink et al. [30, 31, 33] reported a signiﬁcant reduction
in colon tumor incidence and tumor burden in rats fed
defatted soy ﬂour compared to casein-fed control animals.
The purpose of the current investigation was to elucidate
cellular mechanisms underlying colon cancer inhibition
by beans in vivo. Microarrays were performed on mRNA
isolated from distal colonic epithelium of saline and AOM-
injected F344 rats fed either a casein (AIN), black bean (BB),
ordefattedsoyﬂour(SF)dietfor31weeks.Wechosetofocus
on the distal segment because most tumors develop in this
area using standard protocol (15mg/kg AOM) and there
is evidence for site-speciﬁc eﬀects of food constituents on
tumorigenesis [37]. It was anticipated that genes most im-
portant to dietary suppression ofcoloncancerwould be sim-
ilarly aﬀe c t e db yb l a c kb e a n sa n ds o yﬂ o u ra n dh a v ea l t e r e d
expression (increased or decreased) that corroboratedtumor
incidence. The proﬁle of genes altered in this experiment
suggests aberrant activation of innate and adaptive immune
responses are permissive for colon carcinogenesis, whereas
inhibition of tumor promotion by bean feeding is associated
with modulation of genes involved in crypt cell homeostasis,
innate defense, and extracellular matrix components.
2.Materialsand Methods
2.1. Animal Care and Experimental Diets. This study was
conducted in conformity with the regulatory guidelines of
the Michigan State University Institutional Animal Care and
Use Committee. Ninety-ﬁve male Fischer (F344) rats were
obtained from Harlan Sprague-Dawley (Indianapolis, IL) at
3 weeks of age and housed in plastic cages (2-3 rats/cage)
in temperature-(23◦C ± 2◦) and humidity- (40–60%) con-
trolled rooms with a 12-hour light/dark cycle. Throughout
the experiment, animals had free access to food and distilled
water and were assessed daily for health status and monthly
for weight gain.
One control and two experimental diets were formulated
based on the AIN-93G rodent diet with modiﬁcations [38],
to contain the majority (i.e., >85%) of protein from either
(1) high nitrogen casein (AIN), (2) black beans (BB), or (3)
defatted soy ﬂour (SF) (Archer Daniels Midland; Decatur,
IL) and matched to have similar nutrient:energy ratios
(Table 1). Black beans were soaked overnight in distilled
water, cooked in a steam jacket kettle for 30 minutes, dried
at 58◦C, and then ﬁnely ground to pass through a 1.6mm
diameter screen prior to mixing with other diet ingredients.
All diets contained approximately 18.9% (wt/wt) total pro-
tein, 11.3% dietary ﬁber, and 16.7% fat (wt/wt). Casein and
tryptophan were added to black bean diet and methionine
was added to all diets to increase the amino acid score to
>90%. Lard, corn, and soybean oil were added to all diets,
adjusted so the total saturated (SFA):monounsaturated
(MUFA):polyunsaturated (PUFA) fatty acid ratios were
1.0:1.2:1.1, respectively.
2.2. Experimental Design. Upon arrival, animals were fed
the control (AIN) diet and allowed one week to acclimatize
to new conditions. At 4 and 5 weeks of age, rats received
subcutaneous injections (100μL) of either 15mg/kg of azox-
ymethane (AOM) prepared in saline (n = 75; Ash Stevens,
Detroit, MI) or saline (saline, n = 20). Animals were fed
the control (AIN) diet until one week after the second
injection, when they were randomized by weight to either
continue on the control (AIN) diet or to be fed one of the
experimental diets (BB or SF). At 36 weeks of age, animals
were sacriﬁced by CO2 inhalation and exsanguination, and
the colon was immediately excised, opened longitudinally,
andrinsed brieﬂyintapwatertoremovedebris.Macroscopic
tumors, when present, were excised and stored at −80◦C
to be analyzed as a separate part of this study. The colon
was then transected into proximal and distal segments and
epithelial cells were collected by gently scraping normal-
appearingmucosafromthedistalhalfofthecolon(excluding
the lowermost 1cm) with a glass slide. Samples were snap
f r o z e na n ds t o r e da t– 8 0 ◦C until RNA extraction could be
performed.
2.3. Microarray Target Preparation and Hybridization. Af-
fymetrix RU34A rat genome chips (Santa Clara, CA) were
used in this experiment. For total RNA isolation, the
distal colonic mucosa was homogenized using a Tekmar
homogenizer in TRIzol reagent containing RNase-free glyco-
gen according to the manufacturer’s instructions (Gibco,
Carlsbad, CA). After RNA extraction, samples were cleaned
with RNeasy minicolumns (Qiagen, Valencia, CA), quan-
tiﬁed using a UV spectrophotometer (A260/A280), and the
quality of RNA assessed by agarose-formaldehyde gel elec-
trophoresis. Only high quality RNA was used in subsequent
steps.
Biotinylated cRNA was prepared in accordance with
instructions supplied in the GeneChip Expression Manual
(Aﬀymetrix, Santa Clara, CA). Double-stranded cDNA was
synthesized from 10μg of total RNA, pooled from 2–
4animals/treatment, using T7-(dT)24 primers containing a
T7 RNA polymerase promoter site (Proligo, Boulder, CO)
and the Superscript II system (Invitrogen, Carlsbad, CA).
Biotinylated cRNA was prepared using the Enzo BioArray
HighYield RNA Transcript Labeling Kit (Aﬀymetrix, Santa
Clara, CA) and then puriﬁed with RNeasy minicolumns.
Approximately 15μg cRNA was fragmented at 94◦Cf o r3 5
minutes and hybridized to RGU34A rat genome chips for 16
hours at 45◦C. Following hybridization, arrays were washed
and stained with a streptavidin-phycoerythrin conjugate
on an Aﬀymetrix Fluidics station according to standard
protocol. Processed arrays were scanned at 570nm using a
Hewlett Packard GeneArray Scanner.Journal of Nutrition and Metabolism 3
Table 1: Nutrient composition of experimental diets1.
Ingredient g/100g diet
AIN Black bean Soy ﬂour
Casein 20 2.7 —
Black bean ﬂour — 74 —
Defatted soy ﬂour — — 34
Cornstarch 45 — 36
Sucrose 1.8 1.8 1.8
Total lipid2 17 17 17
Total ﬁber in diet3 11 11 11
Mineral mix 3.9 3.9 3.9
Vitamin mix 1.1 1.1 1.1
Methionine 0.33 0.40 0.33
Tryptophan — 0.004 —
Calcium carbonate 0.25 0.25 0.25
Choline bitartrate 0.28 0.28 0.28
Tert-butylhydroquinone 0.002 0.002 0.002
1Nutrient compositions were calculated from the USDA nutrient database and Reeves [38].
2Total lipid content in diets calculated based on natural occurring lipids and added fat. The SFA:MUFA:PUFA composition of all diets was 1:1.2:1.
3Total ﬁber content (11.25%) in all diets based on the amount present from individual dietary components as well as added ﬁber (cellulose).
2.4. Conﬁrmation of Gene Changes by Quantitative Reverse
Transcriptase PCR (qRT-PCR). Select genes were conﬁrmed
using qRT-PCR. Gene-speciﬁc primers for cell division cycle
2( Cdc2),cyclinB1 (Ccnb1), topoisomerase IIalpha (Top2A),
group IIA secretory phospholipase A2 (Pla2g2a), ﬁbronectin
1( Fn1), collagen, type I, alpha 1 (Col1a1), rat neutrophil
(NP) defensin 3 (RatNP-3), aquaporin 8 (Aqp8), and 3-
hydroxy-3-methylglutaryl-Coenzyme Asynthase 2 (Hmgcs2)
were designed with the Primer Express 2.0 program (Applied
Biosystems, Foster City, CA). β- a c t i nw a su s e da sa ni n t e r n a l
control. The sequences of the primer pairs used are available
in Supplementary Table 1 available at doi:10.1155/2012/
351796. Single-stranded (ss) cDNA was synthesized from
2.5μgo ft o t a lR N Au s i n gT 7 - ( d T ) 24 primers (Proligo, Boul-
der,CO)andtheSuperscriptIIsystem(Invitrogen, Carlsbad,
CA). Reverse transcription was performed in a thermocycler
following the Superscript ﬁrst strand synthesis protocol
(Invitrogen, Carlsbad, CA).
Quantitative determination of gene expression was per-
formed with the ABI Prism7000 (Perkin Elmer Corp., Foster
City, CA) using the SYBR Green Universal Master Mix
(Applied Biosystems, Foster City, CA). The reaction mixture
(25μL total volume) contained 20ng ss cDNA, 12.5μL
SYBR Green Universal Master mix, and 10.5μLo fd i l u t e d
primers (300–600nM). The real-time cycle conditions were
as follows: PCR initial activation step at 95◦Cf o r1 5 m i n
and a total of 40 cycles for melting (95◦C, 15s) and anneal-
ing/extension (60◦C, 1min). All assays were performed in
duplicate, using 3-4 samples per group (representing 9–12
animals/group) and relative fold-changes were quantiﬁed by
using the comparative CT (ΔΔCT) method (User bulletin
number 2, Applied Biosystems, Foster City, CA).
2.5. Statistical Analyses. Data for weight gain, microarrays,
and qRT-PCR were analyzed using the General Linear Mod-
els procedure of SAS (SAS Institute, Cary, NC, Version 7.0).
When statistical diﬀerenceswere detectedwith theF statistic,
individual comparisons were made using the least signiﬁcant
diﬀerence (LSD) method. Tumor incidence data were ana-
lyzed with a χ2 test using the Proc Freq procedure in SAS.
Prior to statistical analyses, ﬂuorescence intensity data from
microarraysweregloballyscaledtoatargetintensityof500in
Aﬀymetrix Microarray Suite, Version 5.0 to control within-
chip variations. Globally scaled data were then imported
into GeneSpring (Silicon Genetics, Inc., Redwood City, CA,
Version 6.0) for normalization and ﬁltering. All chips were
normalized to themedian intensity ofa set ofinvariant genes
whose expression across all conditions (injection type, diet)
afterglobalscalingshowedlessthana30%coeﬃcientofvari-
ation (CV). A ﬁltering step excluded genes not considered
“ P r e s e n t ”o r“ M a r g i n a l ”i na tl e a s t4 2 %o ft h ei n d i v i d u a l
samples. An additional ﬁltering step limited the genes fur-
ther to those exhibiting greater than 1.3 or less than 0.7 fold-
change diﬀerence between diets or injection type. Normal-
ized expression values were exported then analyzed using the
GLM procedure of SAS. When present, duplicate transcripts
were averaged prior to statistical analysis.
Diﬀerentially expressed transcripts (P<0.05) were
broadly grouped into categories based on known gene on-
tologies and biological functions reported in the literature.
Gene ontologieswere retrieved using theAﬀymetrixNetAﬃx
Analysis Center (http://www.aﬀymetrix.com/analysis/index
.aﬀx) and DAVID 6.7 functional analysis tool [39, 40]. Data
are presented as mean fold-change diﬀerences standardized
to the AIN (control) group for diet-dependent diﬀerences or4 Journal of Nutrition and Metabolism
to the saline-injected group for injection-dependent chan-
ges.
3.Results
3.1. Weight Gain and TumorIncidence. There were no signif-
icant eﬀects of diet (AIN, BB, SF) or injection regime (AOM
versus saline) on body weight gain. The total weight gain
(g, LSM ± SEM) of rats while on experimental diets was
AIN = 304 ± 7.4, BB = 287 ± 8.3, SF = 299 ± 8.2. There was
as i g n i ﬁ c a n te ﬀect of diet on tumor incidence (P = 0.03).
As previously established, bean-based diets inhibited tumor
incidence by ∼60% compared to rats fed the control diet
(Figure 1).
3.2. Biological Classiﬁcation of Gene Changes in Distal Colonic
Mucosa during AOM-Induced Carcinogenesis. Among the
8799genesandESTspresentontheratgenomeUG34Aarray,
a total of 155 transcripts were signiﬁcantly aﬀected by injec-
tion regime (AOM versus saline), 257 by dietary treatment
(AIN, BB, SF), and 5 were aﬀected by both (P<0.05).
Transcripts diﬀerentially expressed by either carcinogen or
diet were broadly classiﬁed into one of twelve functional
categories and results are depicted in Figure 2.
3.3. Genes Diﬀerentially Expressed by Carcinogen (AOM) in
Distal Colonic Mucosa. A total of108 transcripts were higher
and 47 lower in the colon of rats injected with carcinogen
(AOM) compared to saline-injected controls (P<0.05). As
shown in Figure 2, a majority (55%) of transcripts aﬀected
were associated with immune, defense, inﬂammation (n =
19, 12%), signal transduction (n = 15, 10%), other (n = 17,
11%), or protein processing, synthesis, degradation (n =
20, 13%). Genes involved in antigen presentation (RT1-Ba,
RT1-Da, RT1-Bb, RT1-DMb, RT1-M3-1, RT1-Db1, CD74),
immune, defense, inﬂammation (RatNP-3, Lyz2, Pla2g2a),
and components of the extracellular matrix (Col1a1, Fn1,
Col3a1)w e r ea m o n gt h o s em o s th i g h l yi n d u c e db yA O M -
treatment (Table 2). Several of these genes have previously
beenshowntobeoverexpressedincarcinogen-inducedcolon
cancer [41] and inﬂammatory conditions of the colon [42].
Severalribosomal proteins, includingcomponentsofthe 40S
ribosomal protein subunit (Rps7, Rps15, Rps17, Rps9, Rps4x)
and the 60S unit (Rpl37, Rpl4, Rpl36a) were also moderately
induced by carcinogen compared to saline-injected controls.
3.4. Genes Diﬀerentially Aﬀected by Dietary Treatment in
Distal Colonic Mucosa. Compared to the AIN diet, feeding
rats black beans (BB) signiﬁcantly aﬀected 188 genes (102
upregulated, 86 downregulated), and soy ﬂour (SF) aﬀected
140 genes (97 upregulated, 43 downregulated). Fifty three
genes were signiﬁcantly coinduced and 34 corepressed by
BB and SF, representing 34% of gene changes, although an
additional 24% showed the same direction of change. A
majority of known transcripts aﬀected by dietary treatment
(68%)fell intoone of ﬁvecategories includingother(n = 44,
17%), enzymes (n = 33, 13%), energy metabolism (n = 30,
12%), cell cycle, cell growth and maintenance, and apoptosis
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Figure 1:Tumorincidenceinratstreated withthecarcinogenazox-
ymethane and fed either a casein (AIN control), black bean- (BB-),
or soy ﬂour- (SF-) based diet. ∗Denotes signiﬁcance compared to
AIN controls (P<0.05).
(n = 24, 9.3%), channel, transporter, carrier proteins (n =
22, 8.6%), and signal transduction (n = 22, 8.6%) see
Figure 2.
A select listing of transcripts similarly aﬀected the colon
of bean-fed compared to casein-fed rats is presented in
Table 3. As shown, bean-based diets coinduced a number of
genes involved in fatty acid metabolism and gluconeogenesis
(Hmgcs2, Aldob, Pck1, Ech1), electron transport, oxidore-
ductase, detoxiﬁcation (Cyp4b1, Gstm5, Gstm1, Cyp27a1,
Prdx6), and solute, ion transport (Aqp8, Scnn1g, Slc12a7,
Slc5a1,Slc16a1).Amonggenescorepressedbybeansincluded
those involved in cell cycle (Top2a, Ccnb1, Cdc2), fatty acid
desaturation (Scd1, Scd), extracellular matrix (Col1a1, Fn1),
immune, defense, inﬂammation (Dmbt1, Pla2g2a, RatNP-
3, Tlr4, Ccxl14), and nucleic acid binding, transcription
regulation (Egr1, Egr2).
The relative expression of select genes (Cdc2, Ccnb1,
Top2a, Hmgcs2, and Aqp8) was further evaluated by qRT-
PCR. As shown in Figure 3,t h em R N Af o rCdc2, Ccnb1,
Top2a were all signiﬁcantly lower, whereas Hmgcs2 and Aqp8
were higher in the colon of BB- and SF-fed rats compared
to controls (AIN P<0.05). The direction of change was
generally consistent with those obtained using microarrays
(Table 3).
3.5. GenesAﬀectedby Both Dietary Treatment and Carcinogen
(AOM) in Distal Colonic Mucosa. Five genes were found to
be inﬂuenced both by diet and carcinogen and are presented
in Table 4. Transcripts for phospholipase A2, group IIA
(Pla2g2a), rat neutrophil defensin 3 (RatNP-3), collagen,
type I, alpha 1 (Col1a1), and ﬁbronectin 1 (Fn1)w e r ea l li n -
duced by carcinogen treatment, but to a lower extent in rats
fed either BB or SF. Changes in expression of these genes
were further evaluated by qRT-PCR and results presented
in Figure 4. In accordance with microarray data, there were
signiﬁcant main eﬀects for both diet (P<0.05) and carcino-
gen (P<0.05) treatment for each gene examined. Generally,
expression was lowest in bean-fed rats but increased in allJournal of Nutrition and Metabolism 5
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Figure 2: Functional classiﬁcation of genes signiﬁcantly altered by carcinogen (AOM) and by dietary treatment in the distal colon mucosa
of rats detected by microarrays. A total of 155 genes were altered by carcinogen (AOM) and 257 by dietary treatment (AIN versus BB versus
SF, P<0.05).
dietswithcarcinogeninjections.RatsinjectedwithAOMand
fed the control (AIN) diet had the highest overall expression
levelcoinciding with the higher tumor incidence observed in
these animals. Somatostatin 2 receptor was also inﬂuenced
by both diet and carcinogen treatment, being basally higher
in bean-fed animals and decreasing in all groups following
carcinogen administration (Table 4).
4.Discussion
The focus of the current research was to identify potential
cellular and molecular events underlying suppression of tu-
morigenesisbybeansusing ahighlyrelevantanimal modelof
colon cancer. We proﬁled global changes in gene expression
aﬀected by AOM treatment in normal-appearing colon
mucosa to determine early events permissive for tumor for-
mation and whether these changes could be attenuated by
dietary treatment. Although not a primary focus of this
study, tumor incidence was also assessed. As previously de-
monstrated, both BB- [32]a n dS F - f e d[ 30, 31, 43]r a t s
developedsigniﬁcantlyfewertumorsoverall,conﬁrming that
these diets inhibit experimental colon carcinogenesis. In the
study by Hangen and Bennink [32], however, black and navy
bean- fed-rats ate less and as a result had signiﬁcantly lower
body weights at termination of the study. Because of the
inverse association between energy restriction and tumori-
genesis, the tryptophan and methionine content in the
black bean diets was adjusted to raise the amino acid score
comparable to that of the AIN and SF diets. As a result,
no signiﬁcant diﬀerences in ﬁnal weight gain were detected,
indicating that black beans inhibit tumorigenesis by a mech-
anism other than energy restriction.
We found that AOM treatment most notably aﬀected
genesinvolvedin innate defenseandimmunity. Forexample,
the antimicrobial genes lysozyme, group IIA phospholipase
A2 (Pla2g2a; sPLA2), and neutrophil (NP) defensin 3
(RatNP-3) were approximately 2-fold higher than in saline-
injected controls. Several major histocompatibility class
(MHC) II-associated antigens as well as CD74,t h ec l a s sI I
MHC-associated invariant chain, were also induced in the
colon of AOM-injected rats. Epithelial cells, activated den-
dritic cells, and/or macrophages underlying the intestinal
cell layer can function as antigen-presenting cells [44–48],
and speciﬁc upregulation of these genes implies that car-
cinogen treatment alters immune responsiveness to luminal
and/or bacterial antigens. Additionally, CD74, aside from its6 Journal of Nutrition and Metabolism
Table 2: Select genes signiﬁcantly aﬀected by carcinogen (AOM) treatment in the distal colonic epithelium of male F344 rats1.
Gene symbol Gene title AOM (fold change)
(I) Extracellular matrix, cell adhesion, cytoskeleton
Fn1 ﬁbronectin 1 1.7
Col1a1 collagen, type I, alpha 1 1.6
Vim vimentin 1.5
Tmsb10 thymosin, beta 10 1.3
Col3a1 collagen, type III, alpha 1 1.3
(II) Immune, defense, inﬂammation, stress
Pla2g2a phospholipase A2, group IIA (platelets, synovial ﬂuid) 2.4
Cd74 Cd74 molecule, major histocompatibility complex, class II invariant chain 2.1
Lyz2 lysozyme 2 2.1
RT1-Db1 RT1 class II, locus Db1 2.0
RT1-DMb RT1 class II, locus DMb 1.7
RatNP-3 defensin RatNP-3 precursor 1.7
RT1-Da histocompatibility 2, class II antigen E alpha 1.6
RT1-Ba RT1 class II, locus Ba 1.5
Cxcl13 chemokine (C-X-C motif) ligand 13 1.5
RT1-Bb RT1 class II, locus Bb 1.5
Ccl2 chemokine (C-C motif) ligand 2 1.4
Mif macrophage migration inhibitory factor 1.3
RT1-M3-1 RT1 class Ib, locus M3, gene 1 1.3
Irf7 interferon regulatory factor 7 1.3
Cxcr4 chemokine (C-X-C motif) receptor 4 1.3
Il15 interleukin 15 0.6
(III) Protein processing, synthesis, degradation
Rps7 ribosomalprotein S7 1.4
Rps15 ribosomalprotein S15 1.4
Pfdn2 prefoldin subunit 2 1.4
Hspe1 heat shock protein 1 (chaperonin 10) 1.3
Rpl37 ribosomalprotein L37 1.3
Rpl4 ribosomalprotein L4 1.3
Psmb4 proteasome (prosome,macropain) subunit, beta type 4 1.3
Rpl3l ribosomalprotein L3-like 1.3
Rps4x ribosomalprotein S4, X-linked 1.3
Rps17 ribosomalprotein S17 1.3
Rpl36al ribosomalprotein L36a-like 1.3
Rps9 ribosomalprotein S9 1.3
1Data expressedasmean-foldchange normalized to saline-injectedanimals(n = 12/group). All genes presented were signiﬁcantly altered compared to saline-
injected animals (P<0.05).
classical antigen transporting role, has also been reported
to bind macrophage inhibitory factor (MIF), leading to
nuclear factor kappa B (NFκB) activation, inhibition of p53
phosphorylation, and cell proliferation [49, 50]. Another
cluster of genes inﬂuenced by AOM treatment involved
moderate induction of several ribosomal proteins. RNA and
protein synthesis decrease as cells terminally diﬀerentiate
[51],andenhancedpresenceofribosomal proteintranscripts
is consistent with ﬁndings from other studies in the colon
of rats susceptible to PhIP-induced colon cancer [52]a n di n
animals during aging [53].
Chronic inﬂammation creates an environment permis-
sive to carcinogenesis through enhanced production of lipid
mediators, cytokines, and chemokines that inﬂuence cell
proliferation and apoptosis [54–58]. Additionally generation
of reactive oxygen and nitrogen species either directly or
through activation of phagocytic cells can lead to oxidative
damageofDNA[55,59,60].The mucosalbarrier, comprised
of goblet cell-derived mucin and reinforced by tight junc-
tions normally protects the epithelium and limits activation
ofimmunecellswithinthelamina propria[61–64].Dysfunc-
tions in one or more components of the mucosal barrierJournal of Nutrition and Metabolism 7
Table 3: Genes similarly aﬀected by bean-feeding (BB and SF) in the distal colonic epithelium of male F344 rats1.
Gene symbol Gene title BB SF
(I) Cell cycle, cell growth and maintenance, apoptosis
Ceacam1 carcinoembryonic antigen-related cell adhesion molecule 1 2.3∗ 1.9∗
Rb1 retinoblastoma 1 2.2∗ 2.2∗
Gadd45a growth arrest and DNA-damage-inducible, alpha 1.5∗ 1.5∗
Bax Bcl2-associated X protein 1.3 1.4∗
Egln3 EGL nine homolog 3 (C. elegans) 0.67∗ 0.79
Wfdc1 WAP four-disulﬁde core domain 1 0.67∗ 0.50∗
Ccnb1 cyclin B1 0.66∗ 0.85
Rfc4 replication factor C (activator 1) 4 0.59∗ 1.1
Cdc2 cell division cycle 2, G1 to S and G2 to M 0.58∗ 0.83
Top2a topoisomerase(DNA) II alpha 0.57∗ 0.85
Bub1b budding uninhibited by benzimidazoles 1 homolog,beta (S. cerevisiae) 0.49∗ 0.60∗
(II) Channel, transporters, & carriers
Aqp8 aquaporin 8 2.7∗ 2.9∗
Scnn1g sodium channel, nonvoltage-gated 1 gamma 2.2∗ 2.0∗
Apoa1 apolipoprotein A-I 1.6 2.4∗
Slc12a7 solute carrier family 12 (potassium/chloride transporters), member 7 1.6∗ 1.4∗
Slc5a1 solute carrier family 5 (sodium/glucose cotransporter), member 1 1.5∗ 1.3
Slc16a1 solute carrier family 16, member 1 (monocarboxylic acid transporter 1) 1.5∗ 1.5∗
Atp1a1 ATPase, Na+/K+ transporting, alpha 1 polypeptide 1.4∗ 1.3∗
Lgals9 lectin, galactoside-binding, soluble, 9 1.3∗ 1.3∗
Kcnk1 potassium channel, subfamily K, member 1 1.3∗ 1.3∗
Slco1a1 solute carrier organic anion transporter family, member 1a1 0.68 0.35∗
SLC16A6 solute carrier family 16, member 6 (monocarboxylic acid transporter 7) 0.61∗ 0.82
Fabp5 fatty acid binding protein 5, epidermal 0.48∗ 0.64∗
Ttpa tocopherol (alpha) transfer protein 0.47∗ 0.66∗
(III) Electron transport, oxidoreductase, detoxiﬁcation
Cyp4b1 cytochrome P450, family 4, subfamily b, polypeptide 1 3.6∗ 2.2∗
Gstm5 glutathione S-transferase,mu 5 1.5∗ 1.5∗
Gstm1 glutathione S-transferasemu 1 1.4∗ 1.3
Cyp27a1 cytochrome P450, family 27, subfamily a, polypeptide 1 1.4∗ 1.5∗
Prdx6 peroxiredoxin 6 1.4 1.5∗
Cyp2d1 cytochrome P450, family 2, subfamily d, polypeptide 1 1.4∗ 1.4∗
Por P450 (cytochrome) oxidoreductase 1.4∗ 1.4∗
Cyb5a cytochrome b5 type A (microsomal) 1.4∗ 1.3∗
Tst thiosulfate sulfurtransferase, mitochondrial 1.3∗ 1.3∗
(IV) Energy metabolism
Hmgcs2 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2 2.2∗ 2.1∗
Aldob aldolase B, fructose-bisphosphate 2.1∗ 1.8∗
Pck1 phosphoenolpyruvate carboxykinase 1 (soluble) 2.0∗ 1.8∗
Ech1 enoyl coenzyme A hydratase 1, peroxisomal 1.6∗ 1.6∗
Glul glutamate-ammonialigase 1.4∗ 1.2∗
Hadhb hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-Coenzyme A
thiolase/enoyl-Coenzyme A hydratase (trifunctional protein), beta subunit
1.3∗ 1.3∗
Cbr1 carbonyl reductase 1 1.2 1.5∗8 Journal of Nutrition and Metabolism
Table 3: Continued.
Gene symbol Gene title BB SF
Hadha hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-Coenzyme A
thiolase/enoyl-Coenzyme A hydratase (trifunctional protein), alpha subunit
1.2∗ 1.3∗
Pfkp phosphofructokinase,platelet 0.67∗ 0.76∗
Gpd2 glycerol-3-phosphate dehydrogenase 2, mitochondrial 0.67∗ 0.82
Acsl4 acyl-CoA synthetase long-chain family member 4 0.64∗ 0.80
Pyy peptide YY 0.64∗ 0.72∗
Gcg glucagon 0.57∗ 0.81
Scd stearoyl-CoA desaturase (delta-9-desaturase) 0.53∗ 0.72
Scd1 stearoyl-Coenzyme A desaturase 1 0.47∗ 0.65
(V) Extracellular matrix, cell adhesion, cytoskeleton
Sdc1 syndecan 1 1.3∗ 1.3∗
Sparc secreted protein, acidic, cysteine-rich (osteonectin) 1.0 0.48∗
Fn1 ﬁbronectin 1 0.66∗ 0.61∗
Tubb5 tubulin, beta 5 0.65∗ 0.92
Col1a1 collagen, type I, alpha 1 0.53∗ 0.52∗
(VI) Immune, defense, inﬂammation,stress
Hspa1a heat shock 70kD protein 1A 1.9∗ 1.4
RT1-EC2 RT1 class Ib, locus Aw2 1.5∗ 1.4∗
Tlr4 toll-like receptor 4 0.78∗ 0.68∗
Mif macrophage migration inhibitory factor 0.71∗ 0.88
Dmbt1 deleted in malignantbrain tumors 1 0.64∗ 0.74∗
Pla2g2a phospholipaseA2, group IIA (platelets, synovial ﬂuid) 0.50∗ 0.39∗
RatNP-3 defensin RatNP-3 precursor 0.48∗ 0.69∗
Cxcl14 chemokine (C-X-C motif) ligand 14 0.41∗ 0.48∗
(VII) Nucleic acid binding, transcription regulation
Nr1d2 nuclear receptor subfamily 1, group D, member 2 2.2∗ 1.3
Nﬁb nuclear factor I/B 1.5∗ 1.4∗
Vdr vitamin D (1,25- dihydroxyvitamin D3) receptor 1.4 1.6∗
Syt4 synaptotagminIV 0.82 0.65∗
Egr2 early growth response 2 0.77∗ 0.60∗
Nr4a2 nuclear receptor subfamily 4, group A, member 2 0.70∗ 0.75∗
Egr1 early growth response 1 0.50∗ 0.66∗
(VIII) Signal transduction
Gchfr GTP cyclohydrolase I feedback regulator 1.9∗ 1.8∗
Ppm1b protein phosphatase 1B, magnesium dependent, beta isoform 1.6∗ 1.4
Mapk14 mitogen activated protein kinase 14 1.3∗ 1.4∗
Gucy2c guanylate cyclase 2C 1.3∗ 1.4∗
P2ry2 purinergic receptor P2Y, G-protein coupled 2 0.81 0.61∗
Ptpn3 protein tyrosine phosphatase,non-receptor type 3 0.79∗ 0.73∗
P2ry6 pyrimidinergic receptor P2Y, G-protein coupled, 6 0.69∗ 0.68∗
Pld1 phospholipase D1 0.68∗ 0.85
Ptpn18 protein tyrosine phosphatase,non-receptor type 18 0.63∗ 0.83∗
Ptpro protein tyrosine phosphatase, receptor type, O 0.62∗ 0.72∗
Fzd1 frizzled homolog1 (Drosophila) 0.62∗ 0.74∗
1Data expressed as mean-fold change normalized to the AIN group (n = 8/group). ∗denotes signiﬁcant diﬀerence compared to the control (AIN) diet (P<
0.05).Journal of Nutrition and Metabolism 9
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Figure 3: qRT-PCR analysis of genes for (a) Cdc2,( b )Ccnb1,( c )Top2a,( d )Hmgcs2,a n d( e )Aqp8 in the distal colonic mucosa of rats fed
either an AIN (control), black bean- (BB-), or soy ﬂour- (SF-) based diet. Results were normalized to the housekeeping gene β-Actin
and are presented as relative fold-changes (LSM ± SEM) standardized to the AIN (control) diet. ∗Denotes signiﬁcance compared to AIN
controls; +denotes signiﬁcancebetween BB and SF-fed animals(P<0.05).Abbreviations: Cdc2, cell division cycle 2;Ccnb1,c y c l i nB 1 ;Top2a,
topoisomeraseII alpha; Hmgcs2, 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2; Aqp8, Aquaporin 8.10 Journal of Nutrition and Metabolism
Table 4: Genes signiﬁcantly aﬀected both by carcinogen (AOM) and dietary treatment in the distal colonic epithelium of male F344 rats1.
Gene symbol Gene title Saline-treated AOM-treated
AIN BB SF AIN BB SF
Pla2g2a phospholipase A2, group IIA 1.0 0.64 0.33 2.5 0.97 1.2
RatNP-3 NP defensin 3 1.0 0.44 0.70 1.7 0.78 1.0
Col1a1 collagen, type I, alpha 1 1.0 0.67 0.59 2.3 0.94 0.97
Fn1 ﬁbronectin 1 1.0 0.72 0.77 2.0 1.2 1.0
Sstr2 somatostatin receptor 2 1.0 1.4 1.7 0.69 1.1 1.2
1Data expressed as mean fold-change diﬀerences standardized to the AIN (saline-injected) group (n = 4/group). There were signiﬁcant main eﬀects for injec-
tion type (saline versus AOM) and dietary treatment (AIN versus BB or SF) for eachgene listed (P<0.05).
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Figure 4:Relative fold-changes in (a) Pla2g2a,( b )RatNP-3, (c) Col1a1,a n d( d )Fn1 detected with qRT-PCR. Results were normalizedto the
housekeeping gene β-Actin and are presented as mean fold-changes (LSM ± SEM) relative to the AIN(saline-injected) group. There were
signiﬁcantmain eﬀects for both diet and carcinogen for each gene presented (P<0.05). ∗Denotes signiﬁcanteﬀe c to fd i e tc o m p a r e dt oA I N
controls; δ denotes signiﬁcant eﬀect of carcinogen treatment compared to saline controls (P<0.05). Abbreviations: BB, black bean; SF, soy
ﬂour; Pla2g2a, phospholipase A2, group IIA; RatNP-3, rat neutrophil defensin 3; Col1a1, collagen, type I, alpha 1; Fn1,ﬁ b r o n e c t i n1 .Journal of Nutrition and Metabolism 11
have been implicated in the pathogenesis of inﬂammatory
bowel diseases (IBD) [65–67]a sw e l la si nC R C[ 68–72].
For example, increased intestinal permeability and altered
structure of tight junction proteins precedes relapse in indi-
viduals with IBD [73]. Additionally, Soler et al. [70]n o t e d
defects in tight-junction permeability in normal mucosa
and in colon tumors from carcinogen-treated animals,
and the surface epithelial cells of aberrant crypt foci are
reported to be deﬁcient in mature goblet cells, have altered
mucin composition, and contain irregular microvilli [74].
Alterations in one or more components of the mucosal
barrier would support our ﬁndings of higher immune
responsive genes observed in carcinogen treated animals and
is likely an early and permissive event in promotion of colon
carcinogenesis.
Because both black beans and soy ﬂour reduced tumori-
genesis to a similar extent in this study, we next evaluated
genesthatwere eitherco-inducedorsuppressed comparedto
AIN-fed animals. We identiﬁed several transcripts associated
with proliferation and apoptosis to be regulated in a diet-
dependent manner. An interesting ﬁnding was a 2-fold
higher expression of Ceacam1 in rats fed either BB or SF.
Ceacam1 encodesa cell-surface glycoproteinexpressed in the
diﬀerentiatedcellcompartmentofcoloniccryptsandexpres-
sion correlates positively with normal rates of apoptosis
[75, 76].Atumorsuppressive functionfor Ceacam1 hasbeen
suggested due to loss of expression in hyperplastic polyps,
adenomas, as well as in human colon cancers that precedes
defects in the APC pathway [75]. Somatostatin receptor 2
(Sst2), which mediates anti-proliferative responses to the
hormone somatostatin [77, 78], was also more abundant
in bean-fed animals and levels tended to decrease following
AOM treatment. These results are consistent with decreased
expression of sst2 in human colon tumors [79]a n dw i t h
ﬁndings from Xiao et al. [80] who demonstrated enhanced
colonic mRNA and serum protein levels of somatostatin in
rats fed either whey or soy protein isolate. Bean-fed rats
also exhibited a lower expression of the mitotic genes Ccnb1,
Cdc2,a n dTop2a. Top2a is involved in a variety of processes
including DNA replication, chromosome segregation, and
maintenance of chromosome structure [81]. Protein expres-
sion has been detected primarily in the actively proliferating
cells at the base of the crypt and levels increase during
tumorigenesis [82]. Binding of cyclin B1 to Cdc2 is required
for cells to enter mitosis at the G2 checkpoint [83, 84].
Although these genes can be regulated at the transcriptional
level in a p53-dependent manner [84], the fold change
diﬀerences between diets would more likely suggest an
increase in the proportion of cells undergoing terminal
diﬀerentiation. This is further supported by the anatomical
distribution ofTopoisomerase IIalpha and CEACAM1along
the crypt-lumen axis and implies a general eﬀect of bean-
feeding on maintaining normal crypt cell homeostasis.
Other clustersof genessimilarly aﬀected by bean-feeding
highlightdiﬀerencesinﬁbersourcesoncoloncellphysiology.
For example, the most highly induced class of genes aﬀected
by bean diets included those involved in water channel and
ion transport (Aqp8, Scnn1g, Slc12a7, Tfrc, Slc5a1, Slc16a1)
and energy metabolism (H m g c s 2 ,A l d o b ,P c k 1 ,H a d h b ,E c h 1 ).
These changes are consistent with the physiological eﬀects
of fermentable ﬁbers on intestinal function. Bacterial fer-
mentation of dietary ﬁbers and resistant starch produces
the short-chain fatty acids (SCFA), acetate, propionate, and
butyrate [85, 86]. SCFAs are trophic to the normal colonic
epithelium, enhance water and sodium absorption, increase
mucosal blood ﬂow, and modulate enterohormone release
[87,88].Butyratein particular is an important energy source
forcolonocytesandcaninducegrowtharrest,diﬀerentiation,
and/or apoptosis of colon epithelial cells in vitro [89,
90]. Augenlicht et al. [90, 91]d e m o n s t r a t e dt h a tb u t y r a t e
metabolism, through mitochondrial β-oxidation, is impor-
tant for induction of apoptosis both in vitro and in vivo.
Dsyregulation of genes involved in energy metabolism, such
as Hmgcs2, have been observed in inﬂammatory condi-
tions of the colon [92] and during tumorigenesis [42, 93],
suggesting a potential link between enhanced colonicexpres-
sion and reduced cancer risk.
Despite the large number of genes inﬂuenced by car-
cinogen or diet alone, only 5 transcripts were signiﬁcantly
aﬀected by both treatments. It was originally hypothesized
that gene changes within this group would be the most
important to understanding dietary modulation of tumori-
genesis, with particular interest in those that paralleled
tumor incidence data. We identiﬁed that transcripts for
antimicrobial genes (Pla2g2a, RatNP-3) and extracellular
matrix components (Col1a1, Fn1) were induced by AOM
treatment in all diets, but to a much lesser extent in bean-
fed animals, whereas somatostatin receptor 2 (Sstr2)s h o w e d
the opposite trend. sPLA2 (Pla2g2a) and NP defensin 3
(RatNP-3) exhibit antimicrobial activity and together with
other proteins play an important role in mucosal epithelial
defense[94–100].sPLA2 isamultifunctionalproteininduced
in a variety of inﬂammatory and neoplastic conditions
[101–107]. Enhanced expression has been reported in colon
tumors of patients with familial adenomatous polyposis
[108], in areas adjacent to sporadic colon tumors [109],
in inﬂammatory bowel disease [101, 104, 105, 110], as
well as in carcinogen-induced tumors in rodents [41, 111],
suggesting a promoting role in colonic neoplasia. Aside
from antimicrobial activity [95], sPLA2 may coordinate
immune defenses by enhancing neutrophil function [112]
and contributing to eicosanoid synthesis [103, 113, 114].
Similar to sPLA2, NP defensin 3 exhibits antimicrobial
activity as well as other immune modulatory roles [99, 115,
116]. Normal colonic expression of alpha defensins is low
[96, 97], but expression is induced during inﬂammation
[96, 97, 117, 118], potentially by the proinﬂammatory
cytokines IL-1β,T N F - α,a n dI L - 6[ 119]. Recently, increased
levels of human neutrophil (HNP) defensins 1–3 were
identiﬁed in individuals with colorectal tumors [120–122]
as well as in the serum and colon from patients with
active IBD [117], indicating that alpha defensins may be a
plausible and early biomarker for gastrointestinal disease.
Dietary modulation of these genes in addition to a lower
expression of other innate immune genes, including toll-like
receptor 4 (Tlr4)a n dDmbt1, further suggest bean feeding
inhibits tumor promotion by limiting microbially induced
inﬂammation.12 Journal of Nutrition and Metabolism
Alterations in extracellular matrix (ECM) components
are commonly observed during inﬂammation and carcino-
genesis [123–126] and contribute to number of processes
including cell adhesion and migration, wound healing, angi-
ogenesis, and immune cell migration and activation [123,
127]. Additionally, changes in the distribution and expres-
sion ofdiﬀerent ECM proteins have also beenreported along
the crypt axis [128–130] suggesting a role in normal epithe-
lial migration and diﬀerentiation [130–132]. Col1a1 expres-
sion is upregulated in colon cancer and in other hyperpro-
liferative disorders [133], but normal colonic expression has
notbeenpreviouslyreported.Fibronectinhasbeenidentiﬁed
as a downstream target of the Wnt/β-catenin pathway, which
is frequently altered in colorectal carcinogenesis [134, 135].
Additionally, Kolachala et al. [136] reported expression is
localized to surface epithelial cells and protein levels increase
during the active and restitution phase of dextran sodium-
induced colitis in mice. This was associated with induction
of the α5-integrin receptor, increased cell attachment, and
activation of the NFκB signaling pathway. Although impor-
tant in restitution to injury, several bacteria also contain
binding sites for ﬁbronectin, and increased apical secretion
may inﬂuence adherence to mucosal surfaces, thereby poten-
tiating inﬂammation [137–140]. The lower expression of
these genes in bean-fed animals treated with carcinogen may
represent fewer preneoplastic lesions and/or a more general
eﬀect of diet on maintaining mucosal integrity.
Our ﬁndings provide a strong basis for future studies
on legumes and colon cancer prevention, however, there
are a few limitations to the current study. First, although
microarrays are a powerful tool for biomedical research, one
limitation to this technology is decreased sensitivity for the
detection of low-abundance genes [141]. Additionally, dif-
ferences in gene expression may not directly reﬂect changes
in protein levels nor account for other posttranslational
modiﬁcations such as protein phosphorylation that may also
be involved in dietary modulation of colon cancer [141].
Additional studies should be undertaken to address the
functional involvement of gene changes and corresponding
proteins from this study to further conﬁrm postulated roles
in chemoprevention. Another potential limitation was the
use of colonic mucosal scrapings rather than whole colon
tissue. Mucosal scrapings yield a heterogeneous cell popula-
tion consisting primarily ofcolonocytes,with lesser amounts
ofintraepitheliallymphocytes,macrophages,andendothelial
cells. Although cancer evolves from genetic and epigenetic
alterations arising in epithelial cells, there is increasing
recognition for the importance of the microenvironment
in the carcinogenic process [142]. For example, inﬁltrat-
ing immune cells in the lamina propria may contribute
totumordevelopmentthroughgenerationofreactiveoxygen
species [143, 144] as well as local production of cytokines,
chemokines, and other lipid mediators which can inﬂuence
carcinogenesis by promoting angiogenesis and disrupting
cell cycle regulation [142]. Although our primary interests
were in epithelial gene changes, gene expression patterns in
other cell types were likely underrepresented and should be
considered in future studies to more fully understand the
impact of legumes on colon cancer development.
5.Conclusions
In summary, dietary habits are strongly associated with
colon cancer risk, and this research lends further support
to epidemiological and experimental data that consumption
of bean-based diets inhibits colon cancer development. The
ﬁnding that beans reduce markers of colonic inﬂammation
is consistent with the inverse association of long-term non-
steroidal anti-inﬂammatory drug (NSAID) use on CRC risk
[145, 146]. Further, it is well recognized that individuals
previously treated for colon cancer are at a higher risk of
recurrence of the disease [147]. This observation is proposed
toberelatedtomolecularabnormalitiesinareassurrounding
cancer tissue [148, 149]. Results from this study suggest that
some abnormalities may be related to changes in cytoki-
netics, the innate immune system, and extracellular matrix
components.We speculate dietary modulationofthese genes
is associated with reduced inﬂammation, possibly through
enhancing mucosal barrier function. Conﬁrming some of
these gene changes in humans, further identifying what
causes these changes to occur and determining if bean con-
sumption can reverse these changes would strengthen the
relationship ofbean consumptiononcoloncancerinhibition
and may provide useful adjunct therapy for those at risk.
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